Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS

被引：0
|
作者：
Lee, S. M. [1 ]
Han, B. [2 ]
Peters, S. [3 ]
Le, A. T. [4 ]
Huang, D. [5 ]
Wu, G. [6 ]
Cao, L. [7 ]
Pham, C. P. [8 ]
Zhao, J. [9 ]
Wang, K. [10 ]
Yang, N. [11 ]
Zhong, H. [2 ]
Hu, Y. [12 ]
Morris, S. [12 ]
Lam, V. [13 ]
Graupner, V. [12 ]
Gitlitz, B. [13 ]
Hoglander, E. [12 ]
Schulz, C. [14 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[3] Univ Lausanne, CHU Vaudois, Lausanne, Switzerland
[4] Cho Ray Hosp, Cho Ray Canc Ctr, Ho Chi Minh City, Vietnam
[5] Tianjin Med Univ, Tianjin, Peoples R China
[6] Huazhong Univ, Tongji Med Coll, Wuhan, Peoples R China
[7] Anhui Prov Hosp, Hefei, Peoples R China
[8] Bach Mai Hosp, Nucl Med & Oncol Ctr, Hanoi, Vietnam
[9] Beijing Canc Hosp, Beijing, Peoples R China
[10] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
[11] Hunan Canc Hosp, Changsha, Peoples R China
[12] F Hoffmann La Roche Ltd, Basel, Switzerland
[13] Genentech Inc, San Francisco, CA USA
[14] Univ Hosp Regensburg, Regensburg, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
IPSOS; Atezolizumab; Asian subgroup;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.02-06
引用
收藏
页码：S616 / S617
页数：2
相关论文
共 50 条
  • [1] IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
    Lee, S. M.
    Schulz, C.
    Prabhash, K.
    Han, B.
    Szczesna, A.
    Cortinovis, D. L.
    Rittmeyer, A.
    Vicente Baz, D.
    Califano, R.
    Anh, L. Tuan
    Liu, G.
    Cappuzzo, F.
    Reyes Contreras, J. G.
    Reck, M.
    Hu, Y.
    Morris, S.
    Hoeglander, E. K.
    Connors, M.
    Vollan, H. K. M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1418 - S1419
  • [2] RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
    Lu, S.
    Yu, X.
    Wang, J.
    Zhao, J.
    Yu, Y.
    Hu, C.
    Feng, G.
    Ying, K.
    Zhuang, W.
    Zhou, J.
    Wu, J.
    Leaw, S. J.
    Bai, F.
    Lin, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1019 - S1020
  • [3] Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC
    Reinmuth, Niels
    Spigel, David
    De Marinis, Filippo
    Giaccone, Giuseppe
    Verynenegre, Alain
    Barrios, Carlos Henrique
    Morise, Masahiro
    Felip, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozgueroglur, Mustafa
    Mocci, Simonetta
    Mccleland, Mark
    Enquist, Ida
    Kotnatsubara, Kim
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    Jassem, Jacek
    Herbst, Roy S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 233
  • [4] First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
    Lee, Siow Ming
    Schulz, Christian
    Prabhash, Kumar
    Kowalski, Dariusz
    Szczesna, Aleksandra
    Han, Baohui
    Rittmeyer, Achim
    Talbot, Toby
    Vicente, David
    Califano, Raffaele
    Cortinovis, Diego
    Le, Anh Tuan
    Huang, Dingzhi
    Liu, Geoffrey
    Cappuzzo, Federico
    Contreras, Jessica Reyes
    Reck, Martin
    Palmero, Ramon
    Mak, Milena Perez
    Hu, Youyou
    Morris, Stefanie
    Hoeglander, Elen
    Connors, Mary
    Biggane, Alice M.
    Vollan, Hans Kristian
    Peters, Solange
    LANCET, 2023, 402 (10400): : 451 - 463
  • [5] Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) "platinum-ineligible" patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
    Molina Cerrillo, J.
    Ortego, I.
    Pinto Marin, A.
    Alonso Gordoa, T.
    Puente, J.
    Arranz Arija, J. A.
    Lopez Criado, M. P.
    Gonzalez Morales, A.
    Vidal Cassinello, N.
    Castellano Gauna, D. E.
    Sevillano Fernandez, E.
    Garcia Donas, J.
    Grande Pulido, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S1490 - S1490
  • [6] IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1-selected chemotherapy (chemo)-naive NSCLC patients (pts)
    De Marinis, F.
    Jassem, J.
    Spigel, D. R.
    Lam, S.
    Mocci, S.
    Sandler, A.
    Lopez-Chavez, A.
    Deng, Y.
    Giaccone, G.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC
    Herbst, Roy
    De Marinis, Filippo
    Giaccone, Giuseppe
    Reinmuth, Niels
    Vergnenegre, Alain
    Barrios, Carlos
    Morise, Masahiro
    Font, Enriqueta
    Andric, Zoran
    Geater, Sarayut
    Ozguroglu, Mustafa
    Mocci, Simonetta
    McCleland, Mark
    Enquist, Ida
    Komatsubara, Kim
    Deng, Yu
    Kuriki, Hiroshi
    Wen, Xiaohui
    Jassem, Jacek
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A1 - A1
  • [8] IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC
    Spigel, D.
    de Marinis, F.
    Giaccone, G.
    Reinmuth, N.
    Vergnenegre, A.
    Barrios, C. H.
    Morise, M.
    Felip, E.
    Andric, Z. G.
    Geater, S.
    Ozguroglu, M.
    Mocci, S.
    McCleland, M.
    Enquist, I.
    Komatsubara, K. M.
    Deng, Y.
    Kuriki, H.
    Wen, X.
    Jassem, J.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 915 - 915
  • [9] Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
    Socinski, Mark A.
    Jotte, Robert M.
    Cappuzzo, Federico
    Orlandi, Francisco Jorquera
    Stroyakovskiy, Daniil
    Nogami, Naoyuki
    Rodriguez-Abreu, Delvys
    Moro-Sibilot, Denis
    Thomas, Christian A.
    Barlesi, Fabrice
    Finley, Gene Grant
    Kelsch, Claudia
    Lee, Anthony
    Coleman, Shelley
    Shen, Yijing
    Kowanetz, Marcin
    Lopez-Chavez, Ariel
    Sandler, Alan
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study (vol 402, pg 485, 2023)
    Lee, S. M.
    Schulz, C.
    Prabhash, K.
    LANCET, 2023, 402 (10400): : 450 - 450
12345